Hiroko Nagafuchi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9801273/publications.pdf

Version: 2024-02-01

361413 454955 1,082 34 20 30 citations g-index h-index papers 34 34 34 1218 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The role of HMGB-1 on the development of necrosis during hepatic ischemia and hepatic ischemia/reperfusion injury in mice. Journal of Surgical Research, 2005, 124, 59-66.	1.6	87
2	Comparison of Phenotype and Outcome in Microscopic Polyangiitis Between Europe and Japan. Journal of Rheumatology, 2014, 41, 325-333.	2.0	83
3	Txk, a Nonreceptor Tyrosine Kinase of the Tec Family, Is Expressed in T Helper Type 1 Cells and Regulates Interferon Î ³ Production in Human T Lymphocytes. Journal of Experimental Medicine, 1999, 190, 1147-1154.	8.5	82
4	Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Modern Rheumatology, 2012, 22, 394-404.	1.8	77
5	Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis. Modern Rheumatology, 2012, 22, 405-413.	1.8	7 3
6	Etiopathology of BehÇet's disease: immunological aspects. Yonsei Medical Journal, 1997, 38, 350.	2.2	67
7	Txk, a Member of Nonreceptor Tyrosine Kinase of Tec Family, Acts as a Th1 Cell-Specific Transcription Factor and Regulates IFN- \hat{l}^3 Gene Transcription. Journal of Immunology, 2002, 168, 2365-2370.	0.8	64
8	Fine antigen specificity of human $\hat{I}^3\hat{I}'T$ cell lines ($V\hat{I}^39+$) established by repetitive stimulation with a serotype (KTH-1) of a gram-positive bacterium, Streptococcus sanguis. European Journal of Immunology, 1994, 24, 1536-1543.	2.9	52
9	Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis. Modern Rheumatology, 2012, 22, 405-413.	1.8	48
10	Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Modern Rheumatology, 2012, 22, 394-404.	1.8	45
11	Anatomical and functional recovery by embryonic stem cell-derived neural tissue of a mouse model of brain damage. Journal of the Neurological Sciences, 2004, 219, 107-117.	0.6	42
12	Abnormal killer inhibitory receptor expression on natural killer cells in patients with Behçet's disease. Rheumatology International, 2004, 24, 212-216.	3.0	41
13	Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52. Modern Rheumatology, 2016, 26, 403-409.	1.8	38
14	Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity. Modern Rheumatology, 2009, 19, 283-292.	1.8	37
15	Flk $1+$ cells derived from mouse embryonic stem cells reconstitute hematopoiesis in vivo in SCID mice. Experimental Hematology, 2002, 30, 1444-1453.	0.4	34
16	Serum level of soluble triggering receptor expressed on myeloid cells-1 as a biomarker of disease activity in relapsing polychondritis. Modern Rheumatology, 2014, 24, 129-136.	1.8	32
17	Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease. Journal of the Neurological Sciences, 2015, 349, 143-148.	0.6	32
18	Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity. Modern Rheumatology, 2009, 19, 283-292.	1.8	32

#	Article	IF	CITATIONS
19	Clinical and histopathologic features of 8 patients with microscopic polyangiitis including two with a slowly progressive clinical course. Journal of the American Academy of Dermatology, 2007, 57, 840-848.	1.2	22
20	Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis. Modern Rheumatology, 2015, 25, 603-608.	1.8	21
21	Lack of partial renal response by 12Âweeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV. Arthritis Research and Therapy, 2017, 19, 4.	3.5	18
22	Assessment of the Birmingham vasculitis activity score in patients with MPO-ANCA-associated vasculitis: sub-analysis from a study by the Japanese Study Group for MPO-ANCA-associated vasculitis. Modern Rheumatology, 2014, 24, 304-309.	1.8	12
23	Characterization of Tissue Outgrowth Developed in vitro in Patients with Rheumatoid Arthritis: Involvement of T Cells in the Development of Tissue Outgrowth. International Archives of Allergy and Immunology, 2000, 121, 68-79.	2.1	11
24	AC13, a Câ€ŧerminal fragment of apolipoprotein Aâ€ŀ, is a candidate biomarker for microscopic polyangiitis. Arthritis and Rheumatism, 2011, 63, 3613-3624.	6.7	10
25	Analysis of various factors on the relapse of acute neurological attacks in Behçet's disease. Modern Rheumatology, 2014, 24, 961-965.	1.8	8
26	Establishing clinical remission criteria and the framework of a treat-to-targetÂalgorithm for Takayasu arteritis: Results of a Delphi exercise carried out by an expert panel of the Japan Research Committee of the Ministry of Health, Labour and Welfare for intractable vasculitis. Modern Rheumatology, 2021,	1.8	5
27	Recurrent Bilateral Focal Myositis. Internal Medicine, 2016, 55, 3369-3374.	0.7	3
28	Cutaneous polyarteritis nodosa associated with HLA-B39-positive undifferentiated spondyloarthritis in a Japanese patient. Modern Rheumatology, 2012, 22, 783-786.	1.8	2
29	Assessment of the Birmingham vasculitis activity score in patients with MPO-ANCA-associated vasculitis: sub-analysis from a study by the Japanese Study Group for MPO-ANCA-associated vasculitis. Modern Rheumatology, 2013, , 1.	1.8	1
30	Rheumatoid arthritis relapse in patients with other iatrogenic immunodeficiency-associated lymphoproliferative disorders and its treatment. Modern Rheumatology, 2021, 31, 1087-1093.	1.8	1
31	Clinical features of Behçet's disease patients with joint symptoms in Japan: A national multicenter study. Modern Rheumatology, 2022, 32, 1146-1152.	1.8	1
32	Pregnancy outcomes in patients with rheumatoid arthritis who discontinue methotrexate treatment to conceive. Clinical Rheumatology, 2022, 41, 669-675.	2.2	1
33	Methyl-vitamin B12 blocks the CD28 co-stimulatory pathway in human T cells and its possible therapeutic application for T cell-mediated diseases, including rheumatoid arthritis. Japanese Journal of Rheumatology, 1997, 7, 35-45.	0.0	0
34	Psoriatic Arthritis with Annular Pustular Psoriasis. Internal Medicine, 2016, 55, 519-521.	0.7	0